Premium
Targeting the platelet‐derived growth factor signalling in cardiovascular disease
Author(s) -
Hu Weining,
Huang Yu
Publication year - 2015
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/1440-1681.12478
Subject(s) - medicine , platelet derived growth factor receptor , angiogenesis , imatinib , platelet derived growth factor , growth factor , receptor tyrosine kinase , pathogenesis , imatinib mesylate , inflammation , receptor , cancer research , pharmacology , myeloid leukemia
Summary Over 40 years of studies on platelet‐derived growth factors ( PDGF s) and their receptors, the molecular mechanisms and functional roles of PDGF s in the development of embryos and human diseases, especially in cancer, are gradually being unravelled. PDGF ‐ BB was approved by the United States Food and Drug Administration for promoting wound healing, while imatinib, which selectively inhibits tyrosine kinase activity of PDGF receptors ( PDGFR ), has been prescribed to treat patients with gastrointestinal stromal tumor and chronic eosinophilic leukaemia. However, much less often have these drugs been studied in relation to cardiovascular diseases. This brief review mainly describes the role of PDGF signalling in cardiovascular pathogenesis such as atherosclerosis, pulmonary arterial hypertension, diabetes, angiogenesis and inflammation with an emphasis on how PDGF s function in these situations and what components might serve as potential therapeutic targets against cardio‐metabolic dysfunction.